BiotechTubeBiotechTube
Home/Pipeline/NXP800

NXP800

Platinum-resistant, ARID1a-mutated ovarian cancer

Phase 1bCompleted final data update; biologically active; exploring other opportunities

Key Facts

Indication
Platinum-resistant, ARID1a-mutated ovarian cancer
Phase
Phase 1b
Status
Completed final data update; biologically active; exploring other opportunities
Company
Nuvectis Pharma, Nuvectis Pharma

About Nuvectis Pharma

Nuvectis Pharma is a publicly traded, clinical-stage biotech focused on targeted cancer therapies. Its lead assets are NXP900, a unique Type 1.5 SRC/YES1 inhibitor advancing into Phase 1b trials, and NXP800, a GCN2 activator being explored in ARID1a-mutated ovarian cancer and cholangiocarcinoma. The company is led by a seasoned management team with prior successful drug development and commercialization experience.

View full company profile

About Nuvectis Pharma

Nuvectis Pharma is a publicly traded, clinical-stage biotech focused on targeted cancer therapies. Its lead assets are NXP900, a unique Type 1.5 SRC/YES1 inhibitor advancing into Phase 1b trials, and NXP800, a GCN2 activator being explored in ARID1a-mutated ovarian cancer and cholangiocarcinoma. The company is led by a seasoned management team with prior successful drug development and commercialization experience.

View full company profile

Therapeutic Areas

Oncology